new video loaded: Experts Say GLP-1 Drugs Have Potential Use Beyond Weight Loss
transcript
transcript
Experts Say GLP-1 Drugs Have Potential Use Beyond Weight Loss
Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed the potential for wildly popular weight-loss drugs to be used to treat many other conditions.
-
“Only 25 percent of our persons currently in the United States today, Dec. 4, 2024, do not have overweight and obesity.” “So do you think that 75 percent of the country should be on these drugs?” “I’m not saying that. I’m just saying that we do have a problem.” “Do you think that we’re all in some way going to be on these drugs?” “We’re starting to look at different use case scenarios: things like alcohol use disorder, opiod use disorder. We also were talking about things like Parkinsonism, Alzheimer’s disease. So we’re going to see different disease processes begin to come into the mix when we’re looking at GLP-1 receptor agonists that get outside of the cardiometabolic sphere.” “What did oral contraception do for women? It allowed people to control their reproduction. Maybe the dream scenario here is we can use these medicines to control our urges including food, but maybe other things. And that would be — those studies are going to happen and we’ll know the answer to that. But that would be, I think, a breakthrough across health.”
Recent episodes in DealBook